SARS-CoV-2 Spike Mutants
Recombinant antigens and lentivirus for emerging SARS-CoV-2 variants
During the course of COVID-19 pandemic, several new SARS-CoV-2 variants have emerged, each with differing mutations that can have impacts on transmissibility, COVID-19 disease severity, and effectiveness of vaccines. AMSBIO now offers a series of recombinant antigens and pseudotyped lentivirus with key Spike mutations in order to evaluate the efficacy of antibodies and vaccines. These products form part of our larger COVID-19 Tools for Research portfolio, including other high quality recombinant proteins, Spike pseudotyped lentivirus, and reagents for vaccine development and evaluation.
Spike Mutant Recombinant Proteins
B.1.1.7 and B.1.351 Variants
The B.1.1.7 variant strain (also known as 20B/501Y.V1, VOC 202012/01) of SARS-CoV-2 was first discovered in the United Kingdom in late 2020 with an unusually large number of mutations, including a 69/70 deletion and P681H. Following this, the variant has been detected in multiple countries around the world, including the United States, and is associated with increased transmissibility.
In South Africa, another variant of SARS-CoV-2 (known as 20C/501Y.V2 or B.1.351 lineage) emerged independently of the B.1.1.7 variant. This variant shares some mutations with the B.1.1.7 lineage, but does not contain the deletion at 69/70.
We now provide both B.1.1.7 and B.1.351 lineage SARS-CoV-2 Spike recombinant antigens for COVID-19 research.
These proteins listed below are currently in the pipeline. Contact us if you are interested in any of these antigens and we can provide further information on the product and its availability.
|Protein||Cat. #||Tag||Host||Variant||Mutations||Register Interest|
|S protein||AMS.SPN-C52Hc||His Tag||HEK293||B.1.351||L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V||Contact us if you are interested|
|AMS.SPN-C52H6||B.1.1.7||HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H||Contact us if you are interested|
|S1 protein||AMS.S1N-C52Hd||B.1.1.7||HV69-70del||Contact us if you are interested|
|AMS.S1N-C52Hc||Y144del||Contact us if you are interested|
|AMS.S1N-C52Hg||B.1.1.7/B.1.351||N501Y||Contact us if you are interested|
|AMS.S1N-C52Hb||B.1.1.7||P681H||Contact us if you are interested|
|S1 protein NTD||AMS.S1D-C52H9||B.1.351||L18F, D80A, D215G, R246I||Contact us if you are interested|
|S protein RBD||AMS.SPD-C52Hn||B.1.1.7/B.1.351||N501Y||Contact us if you are interested|
|Nucleocapsid protein||AMS.NUN-C52H8||B.1.1.7||D3L, S235F||Contact us if you are interested|
Spike Mutant Pseudotyped Lentivirus
SARS-CoV-2 Spike D614G Pseudotyped Lentivirus
We provide ready-to-use SARS-CoV-2 Spike Pseudotyped Lentivirus with D614G mutation. This mutation emerged in a variant of SARS-CoV-2 in late January or early February 2020 and was discovered to dramatically increase infectivity of the virus. SARS-CoV-2 viruses carrying this mutation have spread rapidly around many parts of the world due to this transmission advantage. This lentivirus is produced with SARS-CoV-2 Spike with D614G mutation as the envelope glycoproteins instead of the commonly used VSV-G, and can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility. For further information on our other SARS-CoV-2 Spike Pseudotyped Lentiviruses, refer to this page.
Other Spike Mutant Pseudotyped Lentivirus
Spike pseudotyped lentivirus with other key mutations, including N439K, P618H, K417N, E484K and N501Y, can be produced through our Custom Lentivirus Service. These mutations have received a lot of attention due to their ability to either enable the virus to evade antibody-mediated immunity or increase virus infectivity. If you require other Spike mutant pseudotyped lentivirus, you can request these using our Custom Lentivirus Service. Find out more here.